跳转至内容
Merck

1643703

USP

Terconazole

United States Pharmacopeia (USP) Reference Standard

别名:

(+-)-1-{4-[cis-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl}-4-isopropylpiperazine, Triaconazole

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H31Cl2N5O3
CAS号:
分子量:
532.46
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

terconazole

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

InChI

1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1

InChI 密鑰

BLSQLHNBWJLIBQ-OZXSUGGESA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Terconazole USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Ketoconazole
  • Ketoconazole Tablets
  • Terconazole

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

C Schmitt et al.
Obstetrics and gynecology, 76(3 Pt 1), 414-416 (1990-09-01)
Terconazole is the first topical triazole antifungal agent. The results of several European clinical trials have shown both terconazole cream and suppositories to be effective and safe in the treatment of vulvovaginal candidiasis. We conducted a comparative placebo-controlled, double-blind study
J Van Cutsem
American journal of obstetrics and gynecology, 165(4 Pt 2), 1200-1206 (1991-10-01)
The activity of the broad-spectrum triazole antifungal terconazole was evaluated in vitro by the serial decimal dilution technique in broth media. The best correlation between in vitro and in vivo activity was found in brain-heart infusion broth and Eagle's minimum
Fazal Shirazi et al.
Antimicrobial agents and chemotherapy, 57(9), 4360-4368 (2013-07-03)
The high mortality rate of mucormycosis with currently available monotherapy has created interest in studying novel strategies for antifungal agents. With the exception of amphotericin B (AMB), the triazoles (posaconazole [PCZ] and itraconazole [ICZ]) are fungistatic in vitro against Rhizopus
R G García Figueroa et al.
Ginecologia y obstetricia de Mexico, 68, 154-159 (2000-05-29)
A multicenter randomized study was performed. One hundred and seventy patients were selected. The patients were 18 years and older. They presented signs and symptoms of genital candidiasis and had positive smear culture for Candida. Eighty five patients were assigned
M Weisberg
Clinical therapeutics, 11(5), 659-668 (1989-09-01)
Terconazole is a new broad-spectrum antifungal agent for the treatment of vulvovaginal candidiasis. Instead of an imidazole structure, terconazole contains a triazole ring, a structure developed specifically to improve antifungal activity. Clinical studies of this antifungal agent have involved 5,500

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门